Our DNA

Hero section image

Designed to connect research with everyday care

A flexible research site network built around real-world healthcare

Our global network of research sites is designed to expand access to innovative treatments by delivering physical, digital, and human infrastructure to conduct clinical trials wherever patients need them and where leading medical expertise exists. 

Rather than replicating the constraints of traditional site models, we partner with local community healthcare providers and key opinion leaders to embed or establish research capabilities within real-world care settings - empowering them to conduct high-quality clinical research together. Whether through embedded (integrated) models or dedicated sites, we adapt to the local context to ensure trials are seamlessly integrated into care. 

This flexible and scalable model makes clinical trials more accessible, inclusive, and aligned with everyday healthcare, helping to advance our vision of transforming clinical research into a standard option of care.

Mission

We increase access to innovative treatments across various patient populations, in oncology and a broad range of therapeutic areas, elevating healthcare to the next level.

Vision

Our vision is to transform the clinical research landscape by integrating innovative treatments into everyday patient care, making clinical trials a new standard of care option.

Our goal is simple. We bring research closer to everyday care.

By expanding flexible site models and strengthening collaboration with healthcare partners, we are building a future where clinical research becomes a natural part of treatment pathways, especially in oncology.

Portrait of Łukasz Bęczkowski

Łukasz Bęczkowski

CEO

Decades of combined experience

Our story

2014

Beginning of Clinical Trial Operations

It all started in Poland: Clinport with sites in Katowice, Tychy and Dąbrowa Górnicza joined NEUCA - a leading Polish healthcare services company.

2015

Network Expansion through Acquisition

Medica Pro Familia with Research Sites in Katowice, Warsaw, Kraków and Gdynia was acquired

2016

Establishment of Pratia Brand

Establishment of Pratia brand, as NEUCA's Research Network

2018

Investment in Medical Expertise

Investment in Research Sites in Germany (GCP), Spain, Bulgaria, Ukraine and Czech Republic

2019

Launch of Global Initiative

Launch of the Pratia Global Project

2020

Growth and Digital Transformation

Investment in oncology: opening two oncology-focused sites in Poland: in Poznań and Katowice


Investment in Research Sites in Germany (GCP), Spain, Bulgaria, Ukraine and Czech Republic


Launch of Pratia IT Project aiming to run full digital trails in Research Sites


2021

Expansion into Early Phase Research

Investment in MTZ Warsaw (Poland) - a long-established site with a focus on phase I, early clinical development, bioequivalence, and phase III studies


Continued rollout in Germany, Poland, Spain, Czechia, Bulgaria and Ukraine

2024

Strategic Partnerships and European Growth

Establishing sites with UICHI - the oncology unit of Clínical HM Montepríncipe and Llobergat


Partnership with the Spanish Hermes Salud Foundation (with hospitals in Elche, Madrid and Vigo)


Partnership with HLA Universitario Moncloa Hospital (Madrid)


Expansion in Czechia and Slovakia via a strategic acquisition of CRC

2025

Entry into the US Market

Partnership with Essen Health Care in Bronx, New York

2026

Entry into Turkey and further expansion in the US

Acquisition of a majority stake in P1 Trials, a U.S.- based early-phase oncology clinical research network.


Establishment of P1 Pratia Oncology


Majority stake secured in Atlas in Turkey

Broader perspective

Pratia is proud to be part of the Humaneva Group.

Learn more about how out parent company is forging a path to groundbreaking discoveries and the betterment of patient health worldwide: humaneva.com

Humaneva Group graph with its members: Pratia, Kapadi and Hyggio.

Ready to start your clinical trial?

Discover how our flexible approach can support your unique study needs.